NeuroVive Pharmaceutical AB (publ) (STO:NVP) has completed the rights issue approved by an Extraordinary General Meeting on 13 December 2013. The subscription period was 13-27 January 2014. The rights issue was fully subscribed, raising approximately SEK 75.8 m for NeuroVive before issue expenses. Additionally, the Board of Directors has decided to fully exercise its overallocation option of a maximum of 714,286 shares, raising a further SEK 10 m for the company.
Help employers find you! Check out all the jobs and post your resume.
